Transplantation & Cellular Therapy
The latest news, research, and perspectives in transplantation and cellular therapy. Hematopoietic cell transplantation involves replacing unhealthy bone marrow with healthy stem cells in patients with hematologic disorders. In the growing field of non-transplant cellular therapies, including chimeric antigen receptor T-cell therapies, patient- or donor-derived cells are being explored for the treatment and potential cure of blood cancers.
Advertisement
Axi-cel produced sustained long-term responses in patients with follicular lymphoma and marginal zone lymphoma.
A phase II trial found antitumor effect across patient subgroups and independently of risk factors for disease progression.
Treatment with liso-cel was promising in patients with relapsed or refractory follicular lymphoma in TRANSCEND FL.
Manali Kamdar, MD, shared results from the pivotal phase III TRANSFORM study on lisocabtagene maraleucel in LBCL.
Patients with relapsed refractory LBCL can derive clinical benefit from liso-cel NCP without compromising safety.
The median progression-free survival, duration of response, and overall survival were not reached.
Advertisement
Benefits of CAR T-cell therapy outweigh the hypothetical future risk of secondary malignancies.
In approximately 12,000 reports of adverse events, the researchers found 19 cases of T-cell malignancies after CAR-T.
The investigators reviewed case reports of patients 20 years old and younger who underwent therapy for BPDCN.
HMA plus venetoclax was found to be effective and well tolerated in patients with AML who relapsed after HSCT.
Adding ofatumumab to reduced intensity conditioning is safe and effective in high-risk B-cell non-Hodgkin lymphoma.
The study also explored the role of this combination in transitioning patients to HSCT.
The award grants $100,000 to a postdoctoral or early-career oncology researcher from a racial/ethnic minority group.
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
Drs. Dahiya and Spiegel return for the second half of a discussion on reports of secondary T-cell malignancies after CAR-T.
Approach-oriented coping was associated with higher quality of life and lower symptoms of depression and anxiety.
The study used public data from various online sources related to approved CAR-T therapies for MM.
The mandate could affect moving CAR-T therapies into earlier lines of therapy for multiple myeloma.
This manufacturing process change results in a shorter manufacturing time for axi-cel from 16 days to 14 days.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.